Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Kim E. Nichols, MD

Advertisement

Articles by Kim E. Nichols, MD

Kim E. Nichols, MD, of St. Jude Children’s Research Hospital

Dr. Nichols on the Prognosis of Patients With VHL Disease

ByKim E. Nichols, MD
February 17th 2021

Kim E. Nichols, MD, discusses the prognosis of patients with von Hippel-Lindau disease.

Advertisement

Latest Updated Articles

  • Kim E. Nichols, MD, of St. Jude Children’s Research Hospital
    Dr. Nichols on the Prognosis of Patients With VHL Disease

    February 17th 2021



Advertisement
Advertisement

Trending on OncLive

1

Dr Pant on the Potential Significance of Daraxonrasib for PDAC Management

2

Dr Akhade on Building the Evidence Base for Low-Dose Immunotherapy

3

FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

4

EGFR PACC Mutations Define a Distinct NSCLC Subclass With Growing Treatment Options

5

Frontline Choice Anchors Sequencing Decisions in EGFR-Mutated NSCLC

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us